今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

蔚来Q2整车利润重回两位数 NIO Power盈利性指日可待

上海 - 蔚来今日宣布，预计第二季度整车利润将恢复到两位数增长。这表明该公司正在克服供应链挑战和原材料价格上涨带来的影响，盈利能力持续增强。此外，蔚来还重申了对旗下能源服务业务NIO Power的盈利信心。

蔚来联合创始人、总裁李斌表示：“我们很高兴地看到，尽管面临着持续的挑战，蔚来在第二季度展现出强劲的韧性和运营效率。我们预计整车利润将恢复到两位数增长，这表明我们的业务模式具有强大的盈利能力。”

蔚来第一季度净亏损11.2亿元人民币，同比略有扩大。不过，毛利率从去年同期的18.1%提升至20.1%，展现出良好的盈利趋势。

NIO Power方面，蔚来继续扩大充电站网络，并推出新的电池服务计划，以提升用户体验和粘性。蔚来预计，随着NIO Power规模效应的不断显现，该业务将逐步实现盈利。

分析人士指出，蔚来Q2整车利润重回两位数，是公司战略布局和长期投入取得成效的体现。蔚来在智能电动汽车市场处于领先地位，拥有强大的品牌号召力和用户基础。随着产能爬坡和产品结构升级，蔚来有望实现更强的盈利能力。

此外，NIO Power业务的快速发展，也将为蔚来带来新的利润增长点。蔚来已经建立了完善的能源服务体系，包括充电、电池租赁、回收等。随着新能源汽车保有量的快速增长，NIO Power业务将拥有巨大的发展潜力。

总体而言，蔚来的基本面依然稳健，未来发展前景广阔。随着公司持续创新和运营效率的提升，蔚来有望在智能电动汽车市场取得更大的成功。